CL2012003729A1 - Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion. - Google Patents

Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.

Info

Publication number
CL2012003729A1
CL2012003729A1 CL2012003729A CL2012003729A CL2012003729A1 CL 2012003729 A1 CL2012003729 A1 CL 2012003729A1 CL 2012003729 A CL2012003729 A CL 2012003729A CL 2012003729 A CL2012003729 A CL 2012003729A CL 2012003729 A1 CL2012003729 A1 CL 2012003729A1
Authority
CL
Chile
Prior art keywords
benzimidazol
quinolin
piperazin
disintegrant
fluoro
Prior art date
Application number
CL2012003729A
Other languages
English (en)
Inventor
Jeewan Thakur
Zhihui Qiu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012003729A1 publication Critical patent/CL2012003729A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o más rellenos, un desintegrante y un lubricante; proceso de preparación de la composición.
CL2012003729A 2010-06-30 2012-12-28 Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion. CL2012003729A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10168028 2010-06-30

Publications (1)

Publication Number Publication Date
CL2012003729A1 true CL2012003729A1 (es) 2013-04-12

Family

ID=42751565

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003729A CL2012003729A1 (es) 2010-06-30 2012-12-28 Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.

Country Status (37)

Country Link
US (1) US9545402B2 (es)
EP (2) EP3446686A1 (es)
JP (1) JP6043281B2 (es)
KR (2) KR101840182B1 (es)
CN (2) CN103068373A (es)
AR (1) AR081776A1 (es)
AU (1) AU2011273519B2 (es)
BR (1) BR112012033479A8 (es)
CA (1) CA2801826C (es)
CL (1) CL2012003729A1 (es)
CO (1) CO6650354A2 (es)
CR (1) CR20120623A (es)
CU (1) CU20120177A7 (es)
DK (1) DK2588086T3 (es)
DO (1) DOP2012000324A (es)
EA (1) EA026244B1 (es)
EC (1) ECSP13012411A (es)
ES (1) ES2701161T3 (es)
GE (1) GEP20146049B (es)
GT (1) GT201200348A (es)
HU (1) HUE042355T2 (es)
IL (1) IL223799A (es)
MA (1) MA34387B1 (es)
MX (1) MX345404B (es)
MY (2) MY163369A (es)
NI (1) NI201200189A (es)
NZ (1) NZ604055A (es)
PE (1) PE20130481A1 (es)
PL (1) PL2588086T3 (es)
PT (1) PT2588086T (es)
SG (1) SG186182A1 (es)
TN (1) TN2012000574A1 (es)
TR (1) TR201818761T4 (es)
TW (1) TWI583384B (es)
UA (1) UA109659C2 (es)
UY (1) UY33472A (es)
WO (1) WO2012001074A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
AU2013215251A1 (en) 2012-01-31 2014-08-14 Novartis Ag Combination of a RTK inhibitor with an anti - estrogen and use thereof for the treatment of cancer
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
WO2014159609A1 (en) * 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
DK2968529T3 (da) * 2013-03-14 2020-10-12 Aimmune Therapeutics Inc Fremstilling af jordnøddeformuleringer til oral desensibilisering
CN105917270A (zh) 2013-11-15 2016-08-31 视觉力学有限责任公司 具有亲水层的接触透镜
WO2015187736A1 (en) * 2014-06-02 2015-12-10 Allergen Research Corporation Placebo formulations and uses thereof
WO2016094533A1 (en) 2014-12-09 2016-06-16 Ocular Dynamics, Llc Medical device coating with a biocompatible layer
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物
JP2018515566A (ja) * 2015-05-22 2018-06-14 ノバルティス アーゲー 医薬組成物
MX2020004683A (es) 2017-11-02 2020-08-13 Aimmune Therapeutics Inc Metodos de inmunoterapia oral.
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
US10835531B1 (en) 2019-06-18 2020-11-17 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2022026851A1 (en) * 2020-07-31 2022-02-03 The Scripps Research Institute Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
EP1849782A1 (en) 2000-09-11 2007-10-31 Novartis Vaccines and Diagnostics, Inc. Quinolinone derivatives as tyrosine kinase inhibitors
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
MX2007014782A (es) * 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
JP2009517481A (ja) 2005-11-29 2009-04-30 ノバルティス アクチエンゲゼルシャフト キノリノンの製剤
CN101316593B (zh) * 2005-11-29 2012-05-02 诺瓦提斯公司 喹啉酮类的制剂
WO2008112509A1 (en) 2007-03-09 2008-09-18 Novartis Ag Treatment of melanoma
TW200924756A (en) 2007-11-08 2009-06-16 Ambit Biosciences Corp Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
PE20091628A1 (es) * 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
SG184311A1 (en) 2010-04-16 2012-11-29 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
EA201291410A1 (ru) 2013-05-30
US20130090344A1 (en) 2013-04-11
SG186182A1 (en) 2013-01-30
CA2801826A1 (en) 2012-01-05
CO6650354A2 (es) 2013-04-15
GT201200348A (es) 2014-03-14
GEP20146049B (en) 2014-02-25
KR20170139170A (ko) 2017-12-18
KR101840182B1 (ko) 2018-03-19
ES2701161T3 (es) 2019-02-21
MY163369A (en) 2017-09-15
MY177741A (en) 2020-09-23
EP2588086A2 (en) 2013-05-08
CA2801826C (en) 2018-04-10
US9545402B2 (en) 2017-01-17
TR201818761T4 (tr) 2019-01-21
NI201200189A (es) 2013-12-17
WO2012001074A2 (en) 2012-01-05
JP6043281B2 (ja) 2016-12-14
MX345404B (es) 2017-01-30
CN106943355A (zh) 2017-07-14
EP2588086B1 (en) 2018-09-12
JP2013530196A (ja) 2013-07-25
DK2588086T3 (en) 2019-01-07
TWI583384B (zh) 2017-05-21
TW201206903A (en) 2012-02-16
BR112012033479A2 (pt) 2016-11-29
EP3446686A1 (en) 2019-02-27
WO2012001074A3 (en) 2012-03-22
CU20120177A7 (es) 2013-04-19
PE20130481A1 (es) 2013-05-01
CN103068373A (zh) 2013-04-24
EA026244B1 (ru) 2017-03-31
CN106943355B (zh) 2020-09-01
KR20130091319A (ko) 2013-08-16
DOP2012000324A (es) 2013-02-28
PT2588086T (pt) 2018-12-18
ECSP13012411A (es) 2013-03-28
AU2011273519A1 (en) 2013-01-31
PL2588086T3 (pl) 2019-04-30
BR112012033479A8 (pt) 2017-10-31
CR20120623A (es) 2013-02-11
MA34387B1 (fr) 2013-07-03
AR081776A1 (es) 2012-10-17
UA109659C2 (xx) 2015-09-25
HUE042355T2 (hu) 2019-06-28
IL223799A (en) 2017-04-30
MX2012015091A (es) 2013-02-12
UY33472A (es) 2012-01-31
AU2011273519B2 (en) 2014-05-15
TN2012000574A1 (en) 2014-04-01
NZ604055A (en) 2015-02-27

Similar Documents

Publication Publication Date Title
CL2012003729A1 (es) Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.
AR114143A2 (es) Formulaciones de comprimidos revestidos
HRP20190164T1 (hr) Paraziticidni oralni veterinarski sastavi koji obuhvaćaju djelatne tvari sa sustavnim djelovanjem, i načini njihove primjene
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
TW201711676A (en) Ferric citrate dosage forms
SV2010003744A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
BR112014025041B8 (pt) Composição farmacêutica
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
TN2012000477A1 (en) Combination of organic compounds
DOP2015000089A (es) Composición de difenidol de liberación prolongada
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
UY34081A (es) Composición farmacéutica que comprende drotaverina
CL2009000790S1 (es) Desodorizador de aire.
RS54402B1 (en) NIFURATEL SULPHOXIDE FOR USE IN BACTERIAL INFECTION THERAPY
MX2012014498A (es) Composicion farmaceutica de rosuvastatina.
TH1501001478A (th) องค์ประกอบทางเภสัชกรรมสำหรับการให้ทางปากซึ่งมีการละลาย และ/หรือ การดูดซึมดีขึ้น
UY34865A (es) Una composición acuosa que comprende dicamba y un agente de control de la deriva
TR200900104U (tr) Çocuk muayene masası.
UY4219Q (es) Articulo absorbente sanitario
UY4220Q (es) Articulo absorbente sanitario